These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 23170873)

  • 1. Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals.
    Vargas HM; Amouzadeh HR; Engwall MJ
    Expert Opin Drug Saf; 2013 Jan; 12(1):91-102. PubMed ID: 23170873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonclinical development of biopharmaceuticals.
    Baumann A
    Drug Discov Today; 2009 Dec; 14(23-24):1112-22. PubMed ID: 19853058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated and translational nonclinical in vivo cardiovascular risk assessment: gaps and opportunities.
    Berridge BR; Hoffmann P; Turk JR; Sellke F; Gintant G; Hirkaler G; Dreher K; Schultze AE; Walker D; Edmunds N; Halpern W; Falls J; Sanders M; Pettit SD
    Regul Toxicol Pharmacol; 2013 Feb; 65(1):38-46. PubMed ID: 23044254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics.
    Berman CL; Cannon K; Cui Y; Kornbrust DJ; Lagrutta A; Sun SZ; Tepper J; Waldron G; Younis HS
    Nucleic Acid Ther; 2014 Aug; 24(4):291-301. PubMed ID: 24946015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thirty years of preclinical safety evaluation of biopharmaceuticals: Did scientific progress lead to appropriate regulatory guidance?
    Kooijman M; van Meer PJ; Moors EH; Schellekens H
    Expert Opin Drug Saf; 2012 Sep; 11(5):797-801. PubMed ID: 22861668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices.
    Morford LL; Bowman CJ; Blanset DL; Bøgh IB; Chellman GJ; Halpern WG; Weinbauer GF; Coogan TP
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):359-80. PubMed ID: 21770023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety evaluation to support First-In-Man investigations I: kinetic and safety pharmacology studies.
    Baldrick P
    Regul Toxicol Pharmacol; 2008 Jul; 51(2):230-6. PubMed ID: 18501489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals.
    Martin PL; Breslin W; Rocca M; Wright D; Cavagnaro J
    Birth Defects Res B Dev Reprod Toxicol; 2009 Jun; 86(3):176-203. PubMed ID: 19462404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety pharmacology investigations in toxicology studies: an industry survey.
    Authier S; Vargas HM; Curtis MJ; Holbrook M; Pugsley MK
    J Pharmacol Toxicol Methods; 2013; 68(1):44-51. PubMed ID: 23685201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
    Lebrec H; Narayanan P; Nims R
    J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.
    Buckley LA; Chapman K; Burns-Naas LA; Todd MD; Martin PL; Lansita JA
    Int J Toxicol; 2011 Oct; 30(5):583-90. PubMed ID: 22013138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics.
    Vargas HM; Bass AS; Breidenbach A; Feldman HS; Gintant GA; Harmer AR; Heath B; Hoffmann P; Lagrutta A; Leishman D; McMahon N; Mittelstadt S; Polonchuk L; Pugsley MK; Salata JJ; Valentin JP
    J Pharmacol Toxicol Methods; 2008; 58(2):72-6. PubMed ID: 18508287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies and tools for preventing neurotoxicity: to test, to predict and how to do it.
    Llorens J; Li AA; Ceccatelli S; Suñol C
    Neurotoxicology; 2012 Aug; 33(4):796-804. PubMed ID: 22342764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study designs for the nonclinical safety testing of new vaccine products.
    Forster R
    J Pharmacol Toxicol Methods; 2012 Jul; 66(1):1-7. PubMed ID: 22561062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled biopharmaceutical drug development: nonclinical considerations and case studies.
    McElroy MC; Kirton C; Gliddon D; Wolff RK
    Inhal Toxicol; 2013 Mar; 25(4):219-32. PubMed ID: 23480198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appropriate use of recovery groups in nonclinical toxicity studies: value in a science-driven case-by-case approach.
    Pandher K; Leach MW; Burns-Naas LA
    Vet Pathol; 2012 Mar; 49(2):357-61. PubMed ID: 21810619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety Pharmacology Evaluation of Biopharmaceuticals.
    Amouzadeh HR; Engwall MJ; Vargas HM
    Handb Exp Pharmacol; 2015; 229():385-404. PubMed ID: 26091648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies and experimental models for evaluating anesthetics: effects on the developing nervous system.
    Wang C; Slikker W
    Anesth Analg; 2008 Jun; 106(6):1643-58. PubMed ID: 18499593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.